Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Insulin-like growth factor binding protein 5 (IGFBP5) is frequently dysregulated in cancers.
• The specific role and mechanisms of IGFBP5 in human melanoma progression remain unclear.

Purpose of the Study:

• To investigate the function and mechanism of IGFBP5 in melanoma tumorigenicity and metastasis.
• To explore IGFBP5 as a potential therapeutic target for melanoma.

Main Methods:

• Overexpression and knockdown of IGFBP5 in human melanoma cell lines (A375, A2058).
• In vitro assays: proliferation, anchorage-independent growth, migration, invasion.
• In vivo studies: xenograft models, pulmonary metastasis experiments.
• Molecular analyses: epithelial-mesenchymal transition (EMT) markers, stem cell markers, signaling pathway phosphorylation (IGF1R, ERK1/2, p38-MAPK), and transcription factors (HIF1α) and target genes (VEGF, MMP9).
• RNA-sequencing (RNA-Seq) was utilized.

Main Results:

• IGFBP5 overexpression significantly inhibited melanoma cell proliferation, migration, invasion, and in vivo tumor growth and metastasis.
• IGFBP5 suppressed epithelial-mesenchymal transition (EMT) and decreased expression of stem cell markers (NANOG, SOX2, OCT4, KLF4, CD133).
• IGFBP5 reduced phosphorylation of IGF1R, ERK1/2, and p38-MAPK, and decreased HIF1α, VEGF, and MMP9 expression.

Conclusions:

• IGFBP5 acts as a tumor suppressor in melanoma by inhibiting cell malignancy and metastasis.
• IGFBP5 exerts its effects by modulating key signaling pathways and EMT.
• IGFBP5 represents a promising novel therapeutic target for human melanoma.